Articles: sepsis.
-
Intensive care medicine · Mar 2002
Randomized Controlled Trial Multicenter Study Clinical TrialDobutamine and gastric-to-arterial carbon dioxide gap in severe sepsis without shock.
To evaluate the effect of an early dobutamine infusion on gastrointestinal perfusion in patients with severe sepsis. ⋯ An early infusion of dobutamine at a fixed dose of 5 microg/kg per min during the first 72 h of severe sepsis does not influence gastric DeltaCO2.
-
Intensive care medicine · Feb 2002
Multicenter Study Comparative StudyEpidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.
To examine the incidence of infections and to describe them and their outcome in intensive care unit (ICU) patients. ⋯ The crude incidence of ICU infections remains high, although the rate varies between ICUs and patient subsets, illustrating the added burden of nosocomial infections in the use of ICU resources.
-
Critical care medicine · Nov 2001
Randomized Controlled Trial Multicenter Study Clinical TrialSafety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
To assess the safety and effect on coagulopathy of a range of doses of recombinant human activated protein C (rhAPC). To determine an effective dose and duration of rhAPC for use in future clinical trials. ⋯ rhAPC was safe and well-tolerated and demonstrated a dose-dependent reduction in D-dimer and interleukin 6 levels relative to placebo. The dose of 24 microg/kg/hr for 96 hrs was selected for use in future clinical studies.
-
Critical care medicine · Nov 2001
Randomized Controlled Trial Multicenter Study Clinical TrialAssessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
To identify a safe and potentially effective recombinant tissue factor pathway inhibitor (rTFPI) dose for further clinical evaluation in patients with severe sepsis. ⋯ Although the trial was not powered to show efficacy, a trend toward reduction in 28-day all-cause mortality was observed in the all rTFPI group compared with all placebo. This study demonstrates that rTFPI doses of 0.025 and 0.05 mg/kg/hr could be safely administered to severe sepsis patients. Additionally, rTFPI demonstrated bioactivity, as shown by reduction in TATc complexes and interleukin-6 levels. These findings warrant further evaluation of rTFPI in an adequately powered, placebo controlled, randomized trial for the treatment of severe sepsis.
-
Critical care medicine · Jul 2001
Multicenter StudyEpidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
To determine the incidence, cost, and outcome of severe sepsis in the United States. ⋯ Severe sepsis is a common, expensive, and frequently fatal condition, with as many deaths annually as those from acute myocardial infarction. It is especially common in the elderly and is likely to increase substantially as the U.S. population ages.